Savara (NASDAQ:SVRA) Trading Up 3.6%

Savara Inc (NASDAQ:SVRA - Get Free Report)'s stock price shot up 3.6% during mid-day trading on Thursday . The company traded as high as $4.92 and last traded at $4.91. 57,968 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 768,248 shares. The stock had previously closed at $4.74.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SVRA. Piper Sandler upped their price objective on Savara from $7.00 to $16.00 and gave the stock an "overweight" rating in a report on Monday, March 4th. JMP Securities began coverage on Savara in a report on Thursday, February 15th. They set an "outperform" rating and a $8.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $8.20.

Savara Price Performance

The stock has a fifty day moving average of $4.94 and a two-hundred day moving average of $4.34. The stock has a market cap of $737.71 million, a price-to-earnings ratio of -15.88 and a beta of 0.77. The company has a quick ratio of 15.66, a current ratio of 15.66 and a debt-to-equity ratio of 0.19.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02. On average, equities research analysts anticipate that Savara Inc will post -0.38 earnings per share for the current year.

Institutional Trading of Savara

A number of institutional investors have recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of Savara by 22.0% in the fourth quarter. Jane Street Group LLC now owns 20,757 shares of the company's stock valued at $32,000 after acquiring an additional 3,746 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Savara by 19.1% in the third quarter. State Board of Administration of Florida Retirement System now owns 25,780 shares of the company's stock valued at $97,000 after acquiring an additional 4,140 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its position in shares of Savara by 13.7% in the second quarter. Schonfeld Strategic Advisors LLC now owns 57,400 shares of the company's stock valued at $183,000 after acquiring an additional 6,900 shares in the last quarter. Royal Bank of Canada acquired a new position in Savara in the second quarter valued at $25,000. Finally, UBS Group AG increased its stake in Savara by 17.1% in the third quarter. UBS Group AG now owns 54,471 shares of the company's stock valued at $206,000 after purchasing an additional 7,966 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.